H.C. Wainwright raised the firm’s price target on Okyo Pharma to $6 from $5 and keeps a Buy rating on the shares after the FDA cleared the company’s investigational new drug application for a Phase 2 trial of OK-101 for the treatment of neuropathic corneal pain.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OKYO:
- OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
- Okyo Pharma receives FDA approval of IND for OK-101
- Okyo Pharma appoints Perez, Galor, Milner to Scientific Advisory board
- Okyo Pharma price target raised to $5 from $4 at H.C. Wainwright
- Okyo Pharma’s OK-101 achieved statistical significance for two endpoints
